CSIMarket Company Name, Ticker, Suppliers, else..
 
Reshape Lifesciences Inc  (NASDAQ: RSLS)
 
Price: $3.9200 $0.72 22.500%
Day's High: $4.65 Week Perf: 75 %
Day's Low: $ 2.80 30 Day Perf: 38.52 %
Volume (M): 13,741,300 52 Wk High: $ 0.00
Volume (M$): $ 53,866 52 Wk Avg: $0.00
Open: $3.02 52 Wk Low: $0.00



 Market Capitalization (Millions $) 26
 Shares Outstanding (Millions) 7
 Employees 18
 Revenues (TTM) (Millions $) 2
 Net Income (TTM) (Millions $) -11
 Cash Flow (TTM) (Millions $) 9
 Capital Exp. (TTM) (Millions $) 0

Business Description


Reshape Lifesciences Inc is a medical technology company that focuses on developing and commercializing innovative medical devices to treat obesity and metabolic diseases. Their main product is the ReShape® Integrated Dual Balloon System, which is designed to aid in weight loss by occupying space in the stomach and making patients feel full. The company aims to provide non-surgical solutions for patients struggling with obesity, offering an alternative to traditional weight loss methods. In addition to their primary product, Reshape Lifesciences Inc also offers related services such as patient support programs and physician training to ensure successful patient outcomes.


   Company Address: 18 Technology Dr, Suite 110 Irvine 92618 CA
   Company Phone Number: 429-6680   Stock Exchange / Ticker: NASDAQ RSLS


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
JNJ        4.76% 
AXGN   -8.95%    
BDX   -0.27%    
BSX        0.6% 
CNMD   -1.79%    
ISRG        0.75% 
• View Complete Report
   



Stock Market Announcement

ReShape Lifesciences: Strategic Reverse Split & AI Alliance Set to Pave New Path Amid Economic Tides,

Published Wed, May 7 2025 12:31 PM UTC

In a pivotal move aimed at stabilizing its financial position and enhancing shareholder value, ReShape Lifesciences recently announced a 1-for-25 reverse stock split effective at the commencement of trading on May 9, 2025. This significant corporate decision comes amid challenging market conditions, as ReShape Lifesciences share price currently hovers at $5.9447, reflectin...
Contract

AI-Powered Recovery ReShape Lifesciences and Motion Informatics Forge Alliance to Transform U.S. Neurorehab...

Published Thu, Apr 10 2025 10:37 AM UTC

ReShape Lifesciences has announced a groundbreaking partnership with Motion Informatics, positioning itself at the forefront of neurorehabilitation by entering into an exclusive U.S. distribution agreement. This collaboration seeks to introduce AI-driven technology specifically designed to enhance the effectiveness of neuromuscular rehabilitation, marking a significant miles...
Merger and Acquisition

ReShape Lifesciences Sets the Stage for Growth with Vyome Therapeutics Merger and Biorad Medisys Acquisition Amidst Groundbreaking Health Canada Approval,

Published Mon, Jan 13 2025 1:31 PM UTC

Transactions Continue to Progress and Remain on Track Following ReShape Lifesciences Innovative Approaches in Weight Loss and Diabetes Management with New Health Canada Approval and Strategic Research CollaborationsIn an era where health priorities are undergoing significant shifts, ReShape Lifesciences, a frontrunner in weight loss solutions and diabetes management, has ma...
Management Announcement

ReShape Lifesciences Pioneers Innovative Approaches in Weight Loss and Diabetes Management with New Health Canada Approval and Strategic Research Collaborations

Published Tue, Nov 12 2024 1:31 PM UTC

In a remarkable leap forward for obesity management and diabetes treatment, ReShape Lifesciences has recently garnered Health Canada’s approval for its next-generation Lap-Band 2.0, equipped with the innovative FLEX Technology. Designed with the patient s experience at the forefront, this advanced device promises to enhance safety, comfort, and efficacy during weight-loss ...
Product Service News

Collaborating for a Cure ReShape Lifesciences and USC’s CARSS Innovate Next-Gen Diabetes Treatment,

Published Mon, Nov 11 2024 1:31 PM UTC

Unveiling the Future of Diabetes Management: ReShape Lifesciences and USC s CARSS Invest in Groundbreaking Neuromodulation Technology In an exciting development for the diabetes treatment landscape, ReShape Lifesciences, a pioneer in weight-loss solutions, has announced a strategic collaboration with the University of Southern California s Center for Autonomic Nerve Recordin...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 10.83
Price to Sales (Expected) -
Price to Book 3.26
PEG (TTM) -

Financial Strength Current
Quick Ratio 4.1
Working Capital Ratio 4.27
Leverage Ratio (MRQ) 0.43
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -767.11 $
Revenues (TTM) 0.36 $
Cash Flow (TTM) 1.41 $
Cash 1.31 $
Book Value 1.2 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 134,512
Net Income per Employee (TTM) -596,490
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.3

Profitability Ratios Current
Gross Margin (MRQ) 52.69 %
Operating Margin (MRQ) -3576.78 %
Net Margin (MRQ) -3119.63 %
Net Cash Flow Margin (MRQ) 12071.32 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Reshape Lifesciences Inc's Segments
Rest of World    25 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.